Hologic, Inc. $HOLX Shares Acquired by Canada Pension Plan Investment Board

Key Points

• The Canada Pension Plan Investment Board increased its stake in Hologic, Inc. by 8,425.1%, owning 73,657 shares valued at approximately $4.55 million post-acquisition.
• Hologic reported a quarterly EPS of $1.08, surpassing analyst expectations of $1.05, with a net margin of 13.79% and revenue growth of 1.2% year-over-year.
• Analysts have mixed views on Hologic's stock, with ratings ranging from Strong Buy to Hold, and a current consensus price target of $78.00.

Canada Pension Plan Investment Board lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8,425.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 73,657 shares of the medical equipment provider's stock after buying an additional 72,793 shares during the quarter. Canada Pension Plan Investment Board's holdings in Hologic were worth $4,550,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of HOLX. Beverly Hills Private Wealth LLC lifted its stake in Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after acquiring an additional 180 shares in the last quarter. Allworth Financial LP raised its position in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares in the last quarter. Integrated Advisors Network LLC boosted its stake in shares of Hologic by 5.4% in the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock worth $346,000 after buying an additional 289 shares during the last quarter. Townsquare Capital LLC boosted its position in shares of Hologic by 4.5% during the first quarter. Townsquare Capital LLC now owns 6,763 shares of the medical equipment provider's stock worth $418,000 after buying an additional 293 shares during the period. Finally, Empirical Finance LLC increased its position in shares of Hologic by 4.0% during the first quarter. Empirical Finance LLC now owns 8,703 shares of the medical equipment provider's stock worth $538,000 after purchasing an additional 334 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

Shares of HOLX traded down $0.57 during mid-day trading on Monday, reaching $66.19. 563,480 shares of the company's stock traded hands, compared to its average volume of 2,690,686. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The stock has a market capitalization of $14.72 billion, a P/E ratio of 27.46, a price-to-earnings-growth ratio of 2.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The business's 50-day moving average price is $66.34 and its 200-day moving average price is $62.59.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

HOLX has been the subject of a number of research reports. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and raised their target price for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Argus upgraded shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a research report on Monday, August 18th. Stephens reduced their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Evercore ISI upped their target price on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Moderate Buy" and an average price target of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.